8-K: Penumbra Reports Q2 2026 Results Amid Boston Scientific Acquisition

Penumbra, Inc. announced its second quarter 2026 financial results, showing a 14.9% increase in total revenue to $390.0 million, driven by strong performance in both thrombectomy and embolization/access product lines.

Summary

• Penumbra, Inc. reported second quarter 2026 revenue of $390.0 million, a 14.9% increase year-over-year.
• Global thrombectomy revenue grew 12.5% to $259.0 million, while embolization and access revenue increased 20.0% to $131.1 million.
• Gross profit margin improved to 67.9%, up 1.9% from the prior year's second quarter.
• Operating expenses were $223.9 million, including $6.9 million in acquisition-related expenses for the pending Boston Scientific deal.
• Income from operations was $41.0 million, and net income was $34.8 million for the quarter.
• Due to the pending acquisition by Boston Scientific, Penumbra will not provide full-year 2026 financial guidance or host a conference call.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report, with strong operational performance and revenue growth, but tempered by a decrease in net income and the overshadowing effect of the pending acquisition which prevents forward guidance.

Positives

• Total revenue increased by 14.9% to $390.0 million in Q2 2026 compared to Q2 2025.
• Global thrombectomy revenue saw a 12.5% increase, reaching $259.0 million.
• Global embolization and access revenue experienced a significant 20.0% increase, totaling $131.1 million.
• Gross profit margin improved by 1.9% to 67.9% in Q2 2026.
• Net income for the quarter was $34.8 million.

Negatives

• The company will not be providing financial guidance for the full year 2026 due to the pending acquisition.
• Acquisition-related expenses of $6.9 million were incurred in SG&A.
• Net income decreased from $45.3 million in Q2 2025 to $34.8 million in Q2 2026.

Risks

• The pending acquisition by Boston Scientific Corporation may not be completed in the expected timeframe or at all, potentially due to failure to obtain required regulatory approvals.
• Adverse effects to the business may occur during the pendency of the acquisition, such as employee departures or diversion of management's attention.
• Failure to sustain or grow profitability or generate positive cash flows.
• Failure to effectively introduce and market new products or delays in product introductions.
• Significant competition in the market.
• Inability to further penetrate the current customer base, expand the user base, and increase product usage frequency.
• Potential adverse regulatory actions.
• Product defects or failures.

Future Outlook

Penumbra, Inc. will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended June 30, 2026, due to the pending acquisition by Boston Scientific Corporation.

Management Comments

• Penumbra, Inc. reports financial results for the second quarter ended June 30, 2026.
• The company is the world's leading thrombectomy company.

Industry Context

StockSavvy.ai notes that Penumbra's reported revenue growth aligns with the increasing demand for advanced thrombectomy and embolization technologies in treating critical vascular conditions like stroke and pulmonary embolism. The pending acquisition by Boston Scientific highlights the consolidation trend and strategic importance of innovative medical device companies in this sector.

Comparison to Industry Standards

• Penumbra's 14.9% year-over-year revenue growth in Q2 2026 is robust, especially considering the competitive landscape in the medical device sector.
• The 20.0% growth in Embolization and Access revenue outpaces the overall company growth, indicating strong market adoption for these specific product lines.
• A gross profit margin of 67.9% is generally considered healthy for a medical device company, reflecting efficient manufacturing and strong pricing power for its specialized products.

Stakeholder Impact

• Shareholders: The pending acquisition by Boston Scientific will likely result in shareholders receiving cash or stock in Boston Scientific, depending on the deal terms.
• Employees: Uncertainty may arise regarding job security and roles post-acquisition, though growth opportunities within a larger entity could also emerge.
• Customers: Continued access to Penumbra's innovative products is expected, potentially with broader distribution and support through Boston Scientific.
• Suppliers: Potential for consolidated purchasing power and changes in contractual terms under new ownership.

Next Steps

• Completion of the pending acquisition by Boston Scientific Corporation.
• Integration of Penumbra's technologies and operations into Boston Scientific, subject to regulatory approvals.

Key Dates

Recommendation

The company is performing well operationally with solid revenue growth and margin improvement. However, the pending acquisition by Boston Scientific introduces significant uncertainty regarding future standalone performance and guidance. Investors should hold positions to await the closing of the acquisition and understand the terms of the deal and the post-acquisition strategy.

Keywords

thrombectomy, embolization, stroke treatment, pulmonary embolism, acute limb ischemia, medical devices, vascular, neurovascular